Rimonabant
From Buy Rimonabant
Contents |
Rimonabant - Buy Rimonabant Online
What is Rimonabant (Acomplia)?
|
Rimonabant (Acomplia) is an investigational agent for the management of obesity. Rimonabant is developed by Sanofi-Aventis under the name of Acomplia and is a selective CB1 endocannabinoid receptor antagonist indicated for the treatment of obesity. Rimonabant is the first selective CB1 receptor blocker to be approved for use anywhere in the world. In Europe, it is indicated for use in conjunction with diet and exercise for patients with a body mass index greater than 30 kg/m², or patients wih a BMI greater than 27 kg/m² with associated risk factors, such as type 2 diabetes or dyslipidaemia. Rimonabant reduces weight and cardiovascular risk factors in obese people, according to the results of a randomized trial published in the April 16 issue of The Lancet.
How Rimonabant (Acomplia) works?
It works by blocking endogenous cannabinoid binding to neuronal CB1 receptors, activation of these receptors by endoegenous cannabinoids, such as anadamide, increases appetite. It is the most advanced endocannabinoid receptor antagonist in clinical development and offers a novel therapeutic approach to appetite control and weight reduction. Rimonabant may also be found to be effective in assisting some smokers to quit smoking. Sanofi-Aventis is currently conducting studies to determine the possible value of rimonabant in smoking-cessation therapy. The Studies with Rimonabant and Tobacco Use (STRATUS) Program involves more than 6,000 subjects. The drug also has potential as a treatment for smoking cessation because the endocannabinoid system is involved in the body's response to tobacco dependence. "In this study, treatment with rimonabant (acomplia) over one year led to sustained, clinically meaningful weight loss, reduction in waist circumference, and associated improvements in several cardiovascular and metabolic risk factors," lead author Luc Van Gaal, MD, from University Hospital in Antwerp, Belgium, says in a news release.
Is it safe to buy Rimonabant (Acomplia)has it been aproved?
Sanofi-aventis announced on June 23 2005, that the United States Food and Drug Administration (FDA) has accepted for filing the company's New Drug Application (NDA) for rimonabant, the first agent in a new therapeutic class known as selective cannabinoid type 1 (CB1) blockers. Rimonabant, discovered and developed by sanofi-aventis, is thought to represent a new approach for the comprehensive management of cardiovascular risk factors. The compound has been studied to date in over 6,500 overweight and obese adults for up to 2 years. Now that a promising new prescription anti-obesity drug, rimonabant, is actually available in the U.K., Germany and 40 other countries, the launch of the most anticipated weight-loss medication since Fen-phen is generating a great deal of excitement among millions of obese and seriously overweight Americans and Europeans.
More Information about Rimonabant (Acomplia) and latest news
For people that may be interested to buy Rimonabant (Acomplia), they should know that rimonabant is used also other uses. Rimonabant may also be found to be effective in assisting some smokers to quit smoking. Sanofi-Aventis is currently conducting studies to determine the possible value of rimonabant in smoking-cessation therapy. The Studies with Rimonabant and Tobacco Use (STRATUS) Program involves more than 6,000 subjects. STRATUS is designed to explore two smoking-related therapies: first, to use rimonabant directly to aid in smoking cessation; second, to help prevent weight gain in former smokers. Rimonabant reduced resumption of cocaine-seeking responses triggered by two of the three most common triggers of relapse in humans, priming and cues. It may also reduce ethanol and opiate seeking behavior. Tetrahydrocannabinol is known to impair short-term memory. It was therefore hypothesised that Rimonabant may improve short-term memory. Indeed in animal studies it significantly improved the performance of rats to encode information in the short-term memory. Rimobants blocks the psychoactive and some of the cardiovascular effects of Tetrahydrocannabinol in humans without affecting the pharmacokinetics. Acomplia (rimonabant) has been available in Europe since the middle of 2006, you may buy rimonabant online, following regulatory approval by the EMEA in June 2006 for its use as an adjunct to diet and exercise for obese or overweight patients with associated risk factors, such as type 2 diabetes or dyslipidaeamia. At one year, weight loss was greater in patients receiving rimonabant, 5 mg (mean, -3.4 ± 5.7 kg; P = .002 vs placebo) and 20 mg (-6.6 ± 7.2 kg; P < .001 vs placebo) compared with placebo (-1.8 ± 6.4 kg). Weight loss in the rimonabant groups was sustained for around 36 to 40 weeks. The sanofi-aventis Group is the world's third largest pharmaceutical company, ranking number one in Europe.
